ABSTRACT: Initial secure implant fixation predicts long-term survival. Bisphosphonates are anti-resorptive agents. They have been shown to increase implant fixation. We investigated whether local delivery of zoledronate from a poly-D,L-lactide (PDLLA)-coating could improve fixation and osseointegration of hydroxy-apatite coated implants. Cylindrical hydroxy-apatite coated implants were bilaterally inserted press-fit into the proximal tibiae of 10 dogs. On one side the implant was coated with PDLLA containing zoledronate. The PDLLA coating was applied upon the hydroxy-apatite coating. We used the contralateral implant as control. This implant was not coated with a poly-D,L-lactide. Observation period was 12 weeks. We evaluated implant fixation with histomorphometry and biomechanical push-out test. Zoledronate resulted in an approximately threefold increase in all biomechanical parameters when comparing data with their respective controls. We found that zoledronate increased preservation of old lamellar bone and increased formation of new woven bone. This study indicates that local delivery of zoledronate from a PDDLA coating has the potential to increase implant fixation. Studies investigating different doses of zoledronate and longer follow-up are needed. 
More than 1 million total hip arthroplasties are done every year worldwide, and this number is expected to increase in the future. 1 Strategies that improve longterm implant survival are needed. Radiostereometrical analysis (RSA) has shown that early secured implant fixation is important for long-term survical. 2 On way to improve the important early implant fixation could be with the use of bisphosphonates. These drugs are strong inhibitors of osteoclastic bone resorption. 3 Clinical studies have shown that systemic or local treatment can reduce implant migration as measured by RSA. 4, 5 Experimental studies have shown that local or systemic bisphosphonate treatment can increase implant fixation and osseointegration. [6] [7] [8] [9] [10] However, we have previously shown that local bisphosphonate treatment affects bone in a doseresponse relation-ship and that a too high dose can impair implant osseointegration and fixation. 11, 12 Controlled and reproducible methods to local deliver bisphosphonate to the peri-implant bed are important. We have previously shown that zoledronate can be released from a poly (D,L-Lactide)-(PDLLA) coating on a Ti-coated implant in a controlled and reproducible manner and has the ability to increase implant osseointegration and fixation. 13 Other studies have investigated PDDLA as a carrier for growth factors and found it to be tolerated while the growth factors promote bone formation. [14] [15] [16] [17] [18] Clinically, the PDLLA coating is used as a carrier for gentamicin on a commercially available intramedullary tibia nail (UTN PROtect 1 , Synthes GmbH, Oberdorf, Switzerland). 19 Several experimental studies have shown that applying a hydroxy-apatite (HA) coating to a Tiimplant will increase implant osseointegration and fixation. 20, 21 The HA coating improve osseointegration of the implant at the bone-to-implant interface, but has little effect further away form the implant. 20 Implant fixation depend on both a strong bone-toimplant contact and a strong peri-implant bone bed. 22 We have previously shown that zoledronate released from a PDLLA coating has the ability to preserve the peri-implant bone bed while increasing new bone formation. 13 It would be of interest to investigate whether the combined effects of HA at the implant surface and zoledronate, released from a PDDLA coating into the peri-implant bone, would further improve fixation of HA coated implants.
We tested the hypothesis that zoledronate released from a PDDLA surface coating would increase biomechanical fixation and osseointegration of HA-coated experimental implants.
MATERIALS AND METHODS

Study Design
We used 10 skeletally mature female hound dogs with a median weight of 30 kg (range, 27-32 kg). This study was approved by our institutions Animal Care and Use Committee. Institutional guidelines for treatment and care of experimental animals were followed.
Our study was designed as a paired randomized study with 20 implants. We inserted one plasma sprayed HAcoated titanium implant into the proximal aspect of each tibia in 10 dogs. One of the HA-coated implants was coated with PDDLA containing zoledronate and the uncoated contralateral HA-coated implant served as control. We observed the animals for 12 weeks.
We determine sample size from power estimate based on previous studies. 13 We assumed the standard deviation of the relative change to be 50%. Two-sided a and b were set to Grant sponsor: NIH; Grant number: AR 42051. Correspondence to: Thomas Jakobsen (T: þ45-8949-4134; F: þ45-8949-4150; E-mail: thomas.jakobsen@clin.au.dk) 5% and 20%, respectively. Two extra animals were added to the calculated sample size of eight to counteract decreased power if implants from one or two animals were lost for subsequent analysis.
Implants
Our 20 implants consisted of a titanium alloy core (Ti-6Al-4V) onto which a 0.75 mm porous coating was applied by sintering spherical beads (commercially pure Ti). The outermost surface of the implants had a plasma sprayed HA-coating applied. The inner porous Ti coating had an average pore size of 250-300 mm and porosity range of 40-50%.
All porous coated implants were passivated prior to the hydroxyapatite coating process. Plasma spraying hydroxyapatite (HA) onto the porous surface created implants with following specifications as provided by Depuy Orthopaedics, Inc. (Warsaw, IN): HA-coating thickness 40-60 mm, Crystallinity 78.4%, Calcium/Phosphate-ratio 1.67, Tricalciumphosphate 3.29% (w/w) ratio, and Hydroxyapatite 96.71% (w/w) ratio. The implants had a nominal diameter of 6.0 mm and length of 10.0 mm.
The surface coatings were applied by Depuy Orthopaedics, Inc. and donated as a gift.
Poly (D,L-lactide)-Coating
Pure zoledronate (Novartis Pharma AG, Basel, Switzerland) was dissolved in a poly-(D,L-lactide) (PDLLA)-Resomer 203 (Boehringer Ingelheim GmbH, Germany) and ethyl acetate solution resulting in a 2% (w/w) ratio of zoledronate to PDLLA. The solution was stirred for 1 min. The constituents were readily dissolved resulting in a clear solution without debris. Then implants were dipped twice in the solution and air dried under sterile conditions. Based on coating experiments, where the implants where weighed before and after coating, an estimated 0.02 mg zoledronate was incorporated into the PDDLA coating on each implant.
Surgical Procedure
All surgical procedures were performed under sterile conditions with the animals under general anaesthesia. We exposed the proximal anteromedial surface of the tibia through a medial incision. Then we inserted a 2.5 mm guidewire perpendicular into the surface of the proximal part of tibia. Over the guidewire, we used a cannulated drill with an outer diameter of 6.0 mm to make an 11 mm deep cavity. All drilling was done water-cooled and at low speed with two revolutions per second to avoid thermal trauma to the bone. After removing bone-debris and irrigating the cavity, we inserted the implant. We inserted our implant in exact-fit with light hammer blows. In order to avoid potential contamination of our control implant with zoledronate, we inserted the control implant before inserting the PDDLAzoledronate implant in the contralateral tibia. Antibiotics (Rocephin; Sandoz GmbH, Kundl, Austria) were administered immediately before surgery and for the first three postoperative days. Analgesics (Buprenox; Hospira Inc, Lake Forest, IL) were used for the first three postoperative days. All dogs were euthanized 12 weeks postoperatively.
Specimen Preparation
Immediately after euthanasia, we removed the proximal part of each tibia, cleaned it of soft tissue, and stored it at À20˚C. Two specimens containing a part of the implant and surrounding bone were cut from each tibia perpendicular to the long axis of the implant using a water-cooled band saw (Exact Apparatebau, Nordenstedt, Germany) (Fig. 1) . The first and most superficial specimens, with a thickness of 3.5 mm, were stored at À20˚C for later biomechanical testing. The second specimens, with a thickness of 6.5 mm, were fixed in 70% ethanol and used for later histomorphometrical analysis. Preparation of specimens and subsequent evaluation was preformed blinded.
Specimens for histomorphometrical analysis were dehydrated gradually in ethanol (70-100%) containing basic fuchsin, and embedded in methylmethacrylate. We cut four vertical uniform random sections with a hard tissue microtome (KDG-95, MeProTech, Heerhugowaard, The Netherlands) around the central part of each implant. We rotated the implants around their vertical axis before making the section. We cut the 25 mm thick sections with a distance of 400 mm, and counterstained with 2% light-green (BDH Laboratory Supplies, Poole, England).
Biomechanical Testing
We tested implants to failure by axial push-out test on an MTS Bionics Test Machine (MTS, Eden Prairie, MN). We placed the specimens on a metal support jig with a 7.4 mm diameter central opening. Implants were pushed from the peripheral side towards the inside of the bone. A preload of 2 N defined the start of the test. We used a displacement rate of 5 mm/min, and load versus displacement data was continuously recorded. Maximum shear strength (MPa) was determined from the maximum force applied until failure of the bone-implant interface. Maximum shear stiffness (MPa/mm) was obtained from the slope of the linear section of the load versus displacement curve. We calculated total energy absorption (J/m 2 ) as the area under the load displacement curve until failure. We normalized all push-out parameters by the cylindrical surface area of the transverse implant section, as determined from the measured thickness of the individual section tested.
Histomorphometry
We performed blinded quantitative histomorphometry using the stereological software newCAST (Visiopharm A/S, Horsholm, Denmark). Bone-to-implant contact was defined as the implant surface covered with woven or lamellar bone and was estimated by manually counting intercepts between sine-weighted lines and surface covered with bone. Bone volume fractions were estimated by manual point counting to determine the fraction of woven and lamellar bone in two zones around the implants: Zone 1 from the middle of the porous-bead coating and 500 mm into surrounding bone, and Zone 2 in the volume 500-1000 mm from the middle of the porous-bead coating. Bone was surface-stained green, and therefore could clearly be distinguished from the other tissues. Newly formed woven bone was identified by the lack of organization and large, round osteocyte lacunae. Lamellar bone was identified by its highly organized lamellas and lamella-oriented long, oval cell lacunae.
Statistical Analysis
We used Intercooled Stata 9.0 (Stata Inc., College Station, TX) for statistical analysis. Statistical analyses were done on ratios between paired data, which were not normally distributed. All variables were log-transformed and Student's paired t-test was performed on absolute differences between normally distributed log-transformed paired data. Two tailed p-values below 0.05 were considered statistically significant. Results are presented as medians of relative differences between the paired data. The 95% confidence intervals were obtained by back transformation of log-transformed data unless otherwise stated.
RESULTS
No dogs were excluded during the observation period. Implants from one dog for biomechanical testing were excluded as a result of technical error during cutting procedure. No implants for histomorphometrical analysis were excluded.
Biomechanical Analysis
We found that implants coated with PDDLA containing zoledronate had a three to fourfold better fixation in biomechanical parameters when compared with those in the control group (Table 1) .
Histomorphometrical Analysis
We found that zoledronate from the PDDLA coating was able to preserve lamellar bone and increase formation of woven bone in both zone one and two around the implant (Figs. 2 and 3) .
No differences between our two groups were found with respect to lamellar or woven bone in contact with the implant surface (Figs. 2 and 3) .
Histologically, we observed a dense zone of lamellar bone covered with woven bone around the implants in the zoledronate group (Fig. 4) . This is in contrast to the control group were no zone of dense lamellar or woven bone was observed. We found no remnants of the PDDLA coating or delamination of the HA-or Ticoating.
DISCUSSION
We hypothesized that zoledronate released from a PDDLA coating applied on HA-coated implants would improve implant fixation, and osseointegration. We found that zoledronate improved biomechanical implant fixation, preserved lamellar bone, and increased formation of new woven bone.
Our experimental animal model was designed to imitate a cementless HA-coated total joint replacement surrounded by cancellous bone. We choose the canine as test animal since it resembles human bone. 23 Our paired study design allowed us to eliminate effects of biological differences between animals. Although we were able to show positive effects of zoledronate on implant fixation, the results must be interpreted with the limitations of this experimental model in mind. We only investigated the effects of one dose of zoledronate. Extrapolation should be done with caution, since previous studies have shown that high doses of bisphosphonate can impair bone formation. 8, 11 In order to imitation the clinical setting, we choose not to coat our control implant with PDDLA. Any difference between the two treatment groups cannot solely be attributed to zoledronate, but to the combination of zoledronate and PDDLA. However, we know from previous studies that PDDLA alone not has the ability to stimulation bone formation, but impair it. 16, 18, 24 In this study, we used a 2% w/w ratio of zoledronate in the PDDLA coating. This dose is based on a previous studies were the same w/w ratio was able to increase implant fixation and osseointegration in a similar canine model and accelerate fracture healing in a rodent model. 13, 17, 25 We know that there is a strong release of zoledronate within the first hours and that 90% of the zoledronate within the PDDLA coating will be release within 24 h in vitro. 17 Release kinetics in vivo of zoledronate in a PDDLA coating has not been investigated. Furthermore, we do not have any data on the distribution of zoledronate within the coating.
An important finding in this study is the consistent increase in all the biomechanical parameters when comparing our HA-implants with PDDLA containing zoledronate with their respective controls. Fixation of implants is amount other factors dependent on a strong osseointegration and sufficient peri-implant bone stock. 22 We know from previous studies that HAcoating increases bone-to-implant contact and biomechanical fixation. 21 In this study, we are able to improve fixation of HA-coated implants even further. One possible explanation for this could be that the HA-coating and zoledronate in the PDDLA coated exerts their effect at different sites. The HA coating stimulates bone formation at the bone-to-implant interface. Zoledronate are released from the PDDLA coating and diffuses into the peri-implant bone where it preserves lamellar bone and increases formation of new woven bone. The results from this study support the fact that a relative high peri-implant bone density is important for a good biomechanical implant fixation.
The outermost part of the implants is the PDDLA coating. We inserted the porous coated implants in press-fit. With the used study protocol we were not able to control whether any part of the PDDLA coating were ripped of during insertion. However, our results show the even when inserting our PDDLA coated implants in press-fit a positive effect on biomechanical fixation can be found.
With our used dose of zoledronate we were able to preserve old lamellar bone and increase formation of new woven bone. Our findings are consistent with previous studies using a similar animal model were bisphosphonate where able to preserve lamellar bone and increase formation of woven bone. 6, 7, 11 The preservation of old lamellar bone could be explained by the anti-resorptive effect exerted by zoledronate. 26 The increased formation of woven bone could be explained by with the increased amount of lamellar bone that acts as a scaffold and though its osteoconductive properties facilitate new bone formation.
In this study, we used a PDDLA coating as carrier for zoledronate. The PDDLA coating was intended to release zoledronate from the implant surface after which zoledronate was intended to diffuse into the periimplant tissue. We found histological and histomorphometrical effects with increase amount of lamellar and woven bone at least 1 mm away from the implant surface. However, we did not find any differences in the amount of new or old bone at the bone-to-implant surface. We know from previous studies that a hydroxy-apatite coating facilitates bone-to-implant contact. 21 It could be that these osteoconductive properties of HA make it difficult to improve bone-to-implant contact even further.
Several studies have investigated the effect on implant fixation of local administration of bisphosphonate. 9, 10, 27, 28 We have previously shown that there is a dose-response relationship between dose of local bisphosphonate and implant fixation. 11 Furthermore, we have shown that a too high dose can inhibit implant fixation. 12, 29 The results from this present study indicate that zoledronate can be released in a controlled and safe way from a PDDLA coating, diffuse into the peri-implant bone and increase implant fixation. This suggests that there may be a clinical advantage of coating an implant with PDDLA containing zoledronate.
In conclusion, this study indicates that zoledronate released from a PDDLA has the potential to improve fixation of HA-coated implants. The PDDLA coating appears to be a targeted and controlled way to deliver zoledronate to the peri-implant bone. We need further studies that investigate effects of different doses of zoledronate and with longer follow-up.
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